Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.80 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.80 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705033 | 0.89 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL21476817 | 0.84 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2HDAC1HDAC2 | |
| SCHEMBL19860011 | 0.83 | TAS1R3 (0.75) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13736746 | 0.82 | TAS1R3 (0.67) | TAS1R3TAS1R1TAS1R2HDAC1HDAC2 | |
| SCHEMBL13833351 | 0.82 | HDAC2 (0.71) | TAS1R3TAS1R1TAS1R2HDAC1HDAC2 | |
| SCHEMBL13735552 | 0.81 | HDAC1 (0.70) | TAS1R3TAS1R1TAS1R2HDAC1HDAC2 | |
| SCHEMBL704767 | 0.78 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL27102975 | 0.78 | TAS1R3 (0.75) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL3707574 | 0.78 | TAS1R3 (0.75) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13833393 | 0.76 | HDAC2 (0.65) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAC THERAPEUTICS INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9890172-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890172-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HOWARD HUGHES MEDICAL INSTITUTE | 2018-01-18 | — | — | US | disclosed |
| US-9447030-B2 | Inhibitors of histone deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | TAS1R3 3805/4885TAS1R1 4599/4885TAS1R2 4595/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | TAS1R3 3805/4885TAS1R1 4599/4885TAS1R2 4595/4885 |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | TAS1R3 2110/4885TAS1R1 1349/4885TAS1R2 2142/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | TAS1R3 2490/4885TAS1R1 1823/4885TAS1R2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.